Physician profile
Vikas Taneja
NPI 1851606966
$708.38
in general payments reported to CMS, 2019-2025
11 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.38 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.01 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $224.99 | 2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $169.19 | 2025 | Rezdiffra |
| Abbvie INC. | $125.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.91 | 2025 | Xifaxan, Relistor |
| Recordati_rare_diseases_inc. | $26.58 | 2025 | Isturisa |
| Ardelyx, INC. | $23.16 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $22.55 | 2025 | Vowst |
| Sanofi-Aventis U.S. LLC | $21.32 | 2025 | |
| Olympus America INC. | $17.38 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $15.44 | 2025 | Imcivree |
| Novo Nordisk INC | $14.86 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Taneja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.